RGD Reference Report - Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide.

Authors: Morikawa, S  Sone, T  Tsuboi, H  Mukawa, H  Morishima, I  Uesugi, M  Morita, Y  Numaguchi, Y  Okumura, K  Murohara, T 
Citation: Morikawa S, etal., J Am Coll Cardiol. 2009 Mar 24;53(12):1040-6. doi: 10.1016/j.jacc.2008.10.061.
RGD ID: 7247719
Pubmed: PMID:19298916   (View Abstract at PubMed)
DOI: DOI:10.1016/j.jacc.2008.10.061   (Journal Full-text)

OBJECTIVES: This study was designed to examine the protective effects of atrial natriuretic peptide (ANP) on contrast-induced nephropathy (CIN) after coronary angiography. BACKGROUND: Contrast-induced nephropathy is a common complication after angiography. Some studies have shown that ANP has renal protective effects, but the beneficial effects for CIN prevention remain to be clearly shown. METHODS: In a prospective, controlled, randomized trial in 254 consecutive patients with serum creatinine concentrations of > or =1.3 mg/dl, patients received either ANP (0.042 microg/kg/min; ANP group, n = 126) or Ringer solution alone (control group, n = 128). Treatment of either type was initiated 4 to 6 h before angiography and continued for 48 h. RESULTS: There were no significant differences in age, sex, diabetes mellitus, or baseline serum creatinine level between the 2 groups. The prevalence of CIN, defined as a 25% increase in creatinine or an increase in creatinine of > or =0.5 mg/dl from baseline within 48 h, was significantly lower in the ANP group than in the control group (3.2% vs. 11.7%, respectively; p = 0.015). Multivariate analysis revealed that the use of >155 ml of contrast medium (odds ratio: 6.89; p < 0.001) and ANP treatment (odds ratio: 0.24; p = 0.016) were significant predictors of developing CIN. The incidence of an increase in creatinine of > or =25% or of > or =0.5 mg/dl from baseline at 1 month was also significantly lower in the ANP group than in the control group (p = 0.006). CONCLUSIONS: In addition to hydration, ANP administration is effective in the prevention of CIN in patients with chronic renal failure, and the effect was maintained for 1 month.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
NPPAHumanContrast-Induced Nephropathy  IDA  RGD 
NppaRatContrast-Induced Nephropathy  ISONPPA (Homo sapiens) RGD 
NppaMouseContrast-Induced Nephropathy  ISONPPA (Homo sapiens) RGD 

Objects Annotated

Genes (Rattus norvegicus)
Nppa  (natriuretic peptide A)

Genes (Mus musculus)
Nppa  (natriuretic peptide type A)

Genes (Homo sapiens)
NPPA  (natriuretic peptide A)


Additional Information